跳至主要内容
临床试验/NCT07845721
NCT07845721尚未招募不适用

Twelve-Month Outcomes in Children Using MiSight® 1-Day Contact Lenses and Myopia Control Spectacle Lenses as Complementary Myopia Control Interventions.

CooperVision International Limited (CVIL)2 个研究点 分布在 2 个国家目标入组 58 人开始时间: 2026年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
58
试验地点
2
主要终点
Change in axial length (AXL, mm) over 12 months

研究概览

简要总结

Effect of alternating contact lenses and spectacles for myopia control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
11 Years 至 17 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Are aged 11 to 17 years (inclusive);
  • •Have successfully completed the 4-year MiSight® Analysis of Progression (MAP) Study;
  • •Are established soft contact lens wearers (including myopia control contact lens designs);
  • •Have read and signed the study consent or assent form, as appropriate for their age;
  • •Have a parent or legal guardian who has read and signed the Parent/Guardian Information Sheet (PIS) and Consent Form;
  • •Are willing and able to follow study instructions and maintain the appointment schedule;
  • •Are willing to wear the study contact lenses for 10 hours/day and 5 days per week as an ideal target while participating;
  • •Require a spherical contact lens power correction between -0.50 and -6.00 D;
  • •Have astigmatism not exceeding 2.00 DC in each eye by subjective refraction;
  • •Have best-corrected visual acuity of 0.10 logMAR (approx. 20/25 Snellen) or better in each eye;
  • •Have ocular health findings (biomicroscopy) that do not contraindicate contact lens wear;
  • •Continue to demonstrate acceptable fit and handling with the study contact lenses.

排除标准

  • •Are participating in any concurrent clinical or interventional study;
  • •Have worn rigid gas-permeable (including orthokeratology) contact lenses within the previous 30 days;
  • •Have used atropine concentrations above 0.01% for myopia control in the previous 30 days;
  • •Are extended-wear contact lens users (i.e., sleep in their lenses);
  • •Have best-corrected visual acuity worse than 0.10 logMAR in either eye;
  • •Have any current or evolving ocular or systemic condition that could affect visual function, ocular growth, or contact lens wear;
  • •Have any clinically significant corneal or conjunctival staining with sodium fluorescein, or other ocular findings contraindicating contact lens wear;
  • •Are using systemic or topical medications known or expected to affect pupil size, tear production, accommodation, refractive state, or any study outcome variable;
  • •Have a history of ocular surgery, keratoconus, or other forms of irregular cornea, or are aphakic;
  • •Have diagnosed accommodative and/or binocular vision anomalies, including amblyopia, strabismus, or nystagmus;
  • •Have known sensitivity or allergy to any of the diagnostic agents used in the study;
  • •Have any systemic condition that, in the opinion of the investigator, may influence study outcomes or contraindicate soft contact lens wear, including pregnancy;
  • •Are a child of an employee of either clinical site directly involved in the study.

研究组 & 干预措施

Test Group

Experimental

Participants will wear Test Spectacle Lens & Contact Lenses

干预措施: Test Spectacle Lens & Contact Lens (Device)

Control Group

Experimental

Participants will wear Control Spectacle Lens & Contact Lenses

干预措施: Control Spectacle Lens & Contact Lens (Device)

结局指标

主要结局

Change in axial length (AXL, mm) over 12 months

时间窗: Over 12 months

次要结局

未报告次要终点

研究者

发起方
CooperVision International Limited (CVIL)
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验